Nexvet appoints VP of operations
12 August, 2013 by Dylan Bushell-EmblingIP law expert Geraldine Farrell will join Melbourne-based Nexvet as the company’s VP of operations and general counsel.
Viralytics commences trading on OTCQX
12 August, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) ADRs are now being traded on the US-based OTCQX International marketplace.
Dr Rathjen elected Pharmaceuticals Industry Council Chair
08 August, 2013Dr Deborah Rathjen, Managing Director of Bionomics and Chair of AusBiotech, has been elected as the Chair of the Pharmaceuticals Industry Council (PIC). Dr Rathjen will hold this position until at least June 2014.
Victorian young technology entrepreneur challenge
08 August, 2013An opportunity to develop business skills exists for emerging medical device and diagnostics entrepreneurs in Victoria.
Novogen names first member of advisory board
07 August, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has appointed Paul de Souza as chairman of its medical advisory board, which will help the company conduct clinical trials for ovarian cancer drug CS-6.
Prana hiring to help bring PBT2 to market
06 August, 2013 by Dylan Bushell-EmblingPrana Biotechnology (ASX:PBT) has hired former Alchemia CEO Dr Peter Smith to help guide late-stage development of PBT2 in Alzheimer’s and Huntington’s diseases.
iSonea gets TGA listing for AirSonea
06 August, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) has secured an ARTG listing for wheeze-monitoring device AirSonea, paving the way for the Australian launch of the product in September.
Calls to scrap the planned cap on self-education expenses
06 August, 2013AusBiotech has joined the growing chorus of Australian organisations and individuals who are opposed to the federal government’s plan to cap tax deductible self-education expenses at $2000 per Australian resident per annum.
ResMed FY13 profit grows 21%
05 August, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has reported a 21% increase in FY13 net profit, but a decline in profit for the fourth quarter due to its $25m payout to the University of Sydney.
Avita enrols first patients for leg ulcer trial
02 August, 2013 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has signed up the first patients for a trial of its ReCell Spray on Skin product for the new application of treating venous leg ulcers.
Aussie biotechs must plan for weakened dollar
01 August, 2013 by Dylan Bushell-EmblingThe Australian Life Sciences Index outperformed the All Ordinaries in Q4, and the weaker dollar presents both challenges and opportunities for the sector, according to the latest PwC report.
Dr Greg Roger appointed as Medical and Scientific Technologies Supplier Advocate
01 August, 2013Medical technology industry expert Dr Greg Roger has been appointed by the federal government as the Supplier Advocate for the growing medical technologies market.
Bionomics signs up to US$172m deal with Merck
31 July, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has entered a small molecule pain drug research and option agreement with pharmaceutical giant Merck that could be worth up to US$172m.
Biotron completes recruitment for HIV/HCV trial
31 July, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has signed up the 12th and final subject for a phase II open-label trial of BIT225 in patients co-infected with - and receiving treatment for - HIV and HCV.
Student volunteer program for AusBiotech 2013 now open
30 July, 2013Applications are now open for the annual AusBiotech Student Volunteer Program at AusBiotech’s national conference, this year to be held in Brisbane (30 October-1 November).
